Incyte (INCY): financials, SEC filings and peers
Incyte (INCY) is a biotechnology company in the Health Care sector of the S&P 500, headquartered in Wilmington, Delaware.
It was founded in 1991 and joined the S&P 500 on February 28, 2017.
Its fiscal year ends in December, and its shares trade on the Nasdaq.
In its SEC filings it is classified as “Services-Commercial Physical & Biological Research”.
Incyte at a glance
- Revenue (12 months)
- $5.4B
- Revenue growth
- +21.5%
- Operating margin
- 30.0%
- Net income (12 months)
- $1.4B
- Free cash flow (12 months)
- —
- Cash
- $3.5B
- Debt
- —
- Diluted EPS (12 months)
- $7.08
Twelve months to March 31, 2026, from the 10-Q filed April 28, 2026.
Latest twelve months
Over the twelve months to March 31, 2026, Incyte reported revenue of $5.4 billion, up 21.5% from a year earlier.
Its operating margin was 30.0%, up 26.1 percentage points from a year earlier: for every $100 of sales, about $30 was left as operating profit.
Net income was $1.4 billion (26.7% of revenue), 6631.4% higher than a year earlier.
At the end of the period it held $3.5 billion in cash and not reported in debt, a net cash position of $3.5 billion.
The diluted share count rose 4.4% in a year, which dilutes existing shareholders.
Five-year trend
- Revenue went from $2.7 billion in fiscal 2020 to $5.1 billion in fiscal 2025, about 14.0% a year.
- Revenue has grown for 5 fiscal years in a row.
- Operating margin widened from -9.9% to 29.5% over the same years.
- Free cash flow was negative in 1 of the last 3 fiscal years.
- Incyte reported a net loss in 1 of the last 6 fiscal years.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $3.0B | $3.4B | $3.7B | $4.2B | $5.1B |
| Revenue growth | 12.0% | 13.7% | 8.9% | 14.8% | 21.2% |
| Operating margin | 19.6% | 17.1% | 16.8% | 1.4% | 29.5% |
| Net income | $949M | $341M | $598M | $33M | $1.3B |
| Free cash flow | $568M | $892M | — | — | — |
| Diluted EPS | $4.27 | $1.52 | $2.65 | $0.15 | $6.41 |
Fiscal years as reported in Incyte’s 10-K filings. Free cash flow is operating cash flow minus capital spending.
Recent SEC filings
- 8-K filed August 31, 2026 — Other event
- 10-Q filed July 28, 2026 — quarterly report
- 8-K filed July 28, 2026 — Earnings results
- 8-K filed July 6, 2026 — Other event
- 8-K filed June 22, 2026 — Other event
- 8-K filed June 9, 2026 — Shareholder vote results
- 8-K filed June 8, 2026 — Other event
- 10-Q filed April 28, 2026 — quarterly report
Companies like Incyte
Other S&P 500 companies in Biotechnology:
- ABBVAbbVieNorth Chicago, Illinois
- AMGNAmgenThousand Oaks, California
- BIIBBiogenCambridge, Massachusetts
- GILDGilead SciencesFoster City, California
- MRNAModernaCambridge, Massachusetts
- REGNRegeneron PharmaceuticalsTarrytown, New York
- VRTXVertex PharmaceuticalsBoston, Massachusetts
More from Health Care
Questions about Incyte
Is Incyte's revenue growing?
Yes. Revenue for the twelve months to March 31, 2026 was $5.4 billion, up 21.5% from a year earlier, according to its SEC filings.
Is Incyte profitable?
Yes. It earned $1.4 billion in net income over the twelve months to March 31, 2026, a net margin of 26.7%.
When did Incyte last file financial results?
Its latest quarterly report (10-Q) was filed with the SEC on July 28, 2026.
Which companies are similar to Incyte?
In the S&P 500, Incyte is grouped in Biotechnology within the Health Care sector. AbbVie (ABBV), Amgen (AMGN), Biogen (BIIB), Gilead Sciences (GILD), Moderna (MRNA) are in the same group.
Understand the numbers
Source: Incyte’s filings with the U.S. Securities and Exchange Commission (EDGAR), retrieved September 27, 2026. Figures are as reported by the company and may be restated. This page is for information only and is not financial advice.